PE20190371A1 - Anticuerpos de interferon beta y usos de los mismos - Google Patents
Anticuerpos de interferon beta y usos de los mismosInfo
- Publication number
- PE20190371A1 PE20190371A1 PE2018002056A PE2018002056A PE20190371A1 PE 20190371 A1 PE20190371 A1 PE 20190371A1 PE 2018002056 A PE2018002056 A PE 2018002056A PE 2018002056 A PE2018002056 A PE 2018002056A PE 20190371 A1 PE20190371 A1 PE 20190371A1
- Authority
- PE
- Peru
- Prior art keywords
- binding
- antigen
- ifn
- binding fragment
- antibody
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title 1
- 108090000467 Interferon-beta Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012261 overproduction Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Se refiere a un anticuerpo aislado, o fragmento del mismo de enlace al antigeno (que puede comprender una secuencia marco de cadena pesada o ligera de linea germinal humana), que enlaza especificamente el interferon beta (IFN?) humano (tambien puede enlazar un epitopo que comprende uno o mas residuos del grupo involucrado en el enlazamiento del IFN? a su receptor), pudiendo inhibir su enlazamiento a su receptor o competir por ello con otro anticuerpo o fragmento del mismo de enlace al antigeno, teniendo un valor de afinidad de enlazamiento (KD) por lo menos 1000 veces menor que el valor para un IFN? bajo las mismas circunstancias de ensayo. Tambien se refiere a una composicion que comprende a un anticuerpo, o fragmento del mismo de enlace al antigeno, y a un excipiente farmaceuticamente aceptable, y a metodos de produccion y tratamiento. La presente invencion es util para el tratamiento de enfermedades provocadas por sobreproduccion patologica de la expresion del IFN tipo 1, como el lupus eritematoso sistemico (SLE), dermatomitositis (DM) y otras enfermedades reumaticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329327P | 2016-04-29 | 2016-04-29 | |
| US201662339709P | 2016-05-20 | 2016-05-20 | |
| US201762483669P | 2017-04-10 | 2017-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190371A1 true PE20190371A1 (es) | 2019-03-08 |
Family
ID=59215947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018002056A PE20190371A1 (es) | 2016-04-29 | 2017-04-28 | Anticuerpos de interferon beta y usos de los mismos |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10829553B2 (es) |
| EP (2) | EP3448419B1 (es) |
| JP (2) | JP6799076B2 (es) |
| KR (1) | KR102527840B1 (es) |
| CN (1) | CN109069606B (es) |
| AU (1) | AU2017258492B2 (es) |
| BR (1) | BR112018072118A2 (es) |
| CA (1) | CA2965652A1 (es) |
| CO (1) | CO2018012497A2 (es) |
| DK (1) | DK3448419T3 (es) |
| ES (1) | ES2950288T3 (es) |
| FI (1) | FI3448419T3 (es) |
| HR (1) | HRP20230605T1 (es) |
| HU (1) | HUE063621T2 (es) |
| IL (1) | IL262244B2 (es) |
| MX (1) | MX2018013222A (es) |
| MY (1) | MY194084A (es) |
| NZ (1) | NZ747225A (es) |
| PE (1) | PE20190371A1 (es) |
| PH (1) | PH12018502275A1 (es) |
| PL (1) | PL3448419T3 (es) |
| PT (1) | PT3448419T (es) |
| RU (1) | RU2750454C2 (es) |
| SA (1) | SA518400327B1 (es) |
| SG (1) | SG11201809456UA (es) |
| SI (1) | SI3448419T1 (es) |
| TW (1) | TWI776808B (es) |
| WO (1) | WO2017189983A1 (es) |
| ZA (1) | ZA201806682B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2950288T3 (es) | 2016-04-29 | 2023-10-06 | Pfizer | Anticuerpos interferón beta y usos de los mismos |
| EP3672986A1 (en) | 2017-08-22 | 2020-07-01 | Sanabio, LLC | Soluble interferon receptors and uses thereof |
| WO2019209995A2 (en) | 2018-04-25 | 2019-10-31 | Precision Ibd, Inc. | Optimized anti-tl1a antibodies |
| CN116333132A (zh) * | 2019-01-31 | 2023-06-27 | 广东旋玉健康生物科技有限公司 | 新型抗ifnar1抗体 |
| BR112022007720A2 (pt) | 2019-10-24 | 2022-08-23 | Prometheus Biosciences Inc | Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos |
| CN114733455B (zh) * | 2022-04-15 | 2023-02-14 | 北京田园奥瑞生物科技有限公司 | 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物***分型的方法 |
| WO2024062420A1 (en) * | 2022-09-22 | 2024-03-28 | Pfizer Inc. | METHODS OF TREATMENT WITH IFNß ANTIBODIES |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| JP2717319B2 (ja) * | 1988-10-14 | 1998-02-18 | ベルレックス、ラボラトリーズ、インコーポレイテッド | Ｒ―ｉｆｎ―ベータエピトープ部位を代表するペプチド、それに対する抗体、およびその用途 |
| US6682896B1 (en) * | 1988-10-14 | 2004-01-27 | Schering Aktiengesellschaft | Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL108584A (en) * | 1994-02-07 | 2008-03-20 | Yeda Res & Dev | Cloning of the interferon-binding protein ALPHA / BETA |
| ZA9811070B (en) * | 1997-12-08 | 2000-07-03 | Genentech Inc | Type I interferons. |
| WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| KR101250818B1 (ko) | 2002-12-24 | 2013-04-15 | 리나트 뉴로사이언스 코프. | 항-ｎｇｆ 항체 및 그것을 이용하는 방법 |
| JP2014516511A (ja) * | 2011-04-07 | 2014-07-17 | ジェネンテック， インコーポレイテッド | 抗ｆｇｆｒ４抗体及び使用方法 |
| CN102898521A (zh) * | 2011-07-26 | 2013-01-30 | 上海市免疫学研究所 | 抗β-干扰素单克隆抗体及其应用 |
| US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| IL256424B1 (en) * | 2015-06-26 | 2024-05-01 | Bioverativ Usa Inc | Methods for treating autoimmune and alloimmune disorders |
| ES2950288T3 (es) | 2016-04-29 | 2023-10-06 | Pfizer | Anticuerpos interferón beta y usos de los mismos |
-
2017
- 2017-04-28 ES ES17733171T patent/ES2950288T3/es active Active
- 2017-04-28 BR BR112018072118-2A patent/BR112018072118A2/pt unknown
- 2017-04-28 CA CA2965652A patent/CA2965652A1/en active Pending
- 2017-04-28 AU AU2017258492A patent/AU2017258492B2/en active Active
- 2017-04-28 KR KR1020187034153A patent/KR102527840B1/ko active IP Right Grant
- 2017-04-28 PL PL17733171.7T patent/PL3448419T3/pl unknown
- 2017-04-28 FI FIEP17733171.7T patent/FI3448419T3/fi active
- 2017-04-28 HU HUE17733171A patent/HUE063621T2/hu unknown
- 2017-04-28 PT PT177331717T patent/PT3448419T/pt unknown
- 2017-04-28 US US15/581,079 patent/US10829553B2/en active Active
- 2017-04-28 SG SG11201809456UA patent/SG11201809456UA/en unknown
- 2017-04-28 CN CN201780025961.XA patent/CN109069606B/zh active Active
- 2017-04-28 SI SI201731384T patent/SI3448419T1/sl unknown
- 2017-04-28 EP EP17733171.7A patent/EP3448419B1/en active Active
- 2017-04-28 IL IL262244A patent/IL262244B2/en unknown
- 2017-04-28 EP EP23177086.8A patent/EP4273165A3/en active Pending
- 2017-04-28 TW TW106114362A patent/TWI776808B/zh active
- 2017-04-28 MX MX2018013222A patent/MX2018013222A/es unknown
- 2017-04-28 MY MYPI2018703975A patent/MY194084A/en unknown
- 2017-04-28 DK DK17733171.7T patent/DK3448419T3/da active
- 2017-04-28 PE PE2018002056A patent/PE20190371A1/es unknown
- 2017-04-28 HR HRP20230605TT patent/HRP20230605T1/hr unknown
- 2017-04-28 WO PCT/US2017/030089 patent/WO2017189983A1/en active Application Filing
- 2017-04-28 JP JP2018556490A patent/JP6799076B2/ja active Active
- 2017-04-28 NZ NZ747225A patent/NZ747225A/en unknown
- 2017-04-28 RU RU2018141839A patent/RU2750454C2/ru active
-
2018
- 2018-10-08 ZA ZA2018/06682A patent/ZA201806682B/en unknown
- 2018-10-25 PH PH12018502275A patent/PH12018502275A1/en unknown
- 2018-10-28 SA SA518400327A patent/SA518400327B1/ar unknown
- 2018-11-21 CO CONC2018/0012497A patent/CO2018012497A2/es unknown
-
2020
- 2020-11-09 US US17/092,998 patent/US11858986B2/en active Active
- 2020-11-19 JP JP2020192541A patent/JP7102489B2/ja active Active
-
2023
- 2023-11-16 US US18/511,744 patent/US20240174742A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190371A1 (es) | Anticuerpos de interferon beta y usos de los mismos | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| CU20180136A7 (es) | Anticuerpos monoclonales aislados que compiten por la union a tau con el anticuerpo 16g7 | |
| CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
| CL2019001324A1 (es) | Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos. | |
| PE20160993A1 (es) | Nuevos anticuerpos anti-dpep3 y metodos de uso | |
| BR112018067679A2 (pt) | células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso | |
| PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
| BR112017014805A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123 | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| UY37457A (es) | Compuestos de anticuerpos acoplados de tirosina-tirosina cíclica como moduladores de receptores del neuropeptido y | |
| BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| PE20190440A1 (es) | Anticuerpos a la alfa-sinucleina y usos de los mismos | |
| CL2016001968A1 (es) | Proteinas de fusion de interleucina-2 y usos de las mismas | |
| BR112019005726A8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno | |
| CO2019014286A2 (es) | Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas | |
| BR112017022008A2 (pt) | composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios | |
| CL2019000999A1 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos. | |
| CL2018001238A1 (es) | Moléculas de unión específicas para asct2 y usos de las mismas | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| BR112015018035A2 (pt) | anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno |